Fennec Pharmaceuticals Inc. reported $59M of revenue over the trailing twelve months, +78% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $59M (to Q2 2026). Net income: −$3.3M, trailing twelve months to Q2 2026. Operating margin: −2.8%, trailing twelve months to Q2 2026. EPS: −$0.12, trailing twelve months to Q2 2026.

FENCFennec Pharmaceuticals Inc.

Healthcare

$10.65+12% 1Y

$10.65

$5.7752 weeks$12.78

FENC as reported

Fennec Pharmaceuticals Inc. reported $59M of revenue over the trailing twelve months, +78% on the year before. 10 reported series are charted on this page, each one as filed.

$59M

Revenue, trailing twelve months · to Q2 2026 · +78% against the twelve months before

Net income: −$3.3M
Net income · −73% year on year · trailing twelve months to Q2 2026
Operating margin: −2.8%
Operating margin · trailing twelve months to Q2 2026
EPS: −$0.12
EPS · −73% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for FENC, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$59M	+78%	Q2 2026
Net income	−$3.3M	−73%	Q2 2026
EPS	−$0.12	−73%	Q2 2026
Gross margin	94%	n/a	Q4 2023 · 10 quarters behind
Operating margin	−2.8%	n/a	Q2 2026
Net margin	−6.9%	n/a	Q2 2026
ROE	24%	n/a	Q2 2026
ROA	−11%	n/a	Q2 2026
ROIC	63%	n/a	Q3 2025
Free cash flow	−$1.7M	n/a	Q4 2014 · 46 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.